FDA Declares End to Tirzepatide Shortage, Impacting Compounded Drug Market

Eli Lilly's weight-loss and diabetes medications Mounjaro and Zepbound are now meeting national demand, altering the landscape for off-brand versions.

The FDA confirmed the resolution of the tirzepatide shortage, which has persisted since 2022 due to high demand for GLP-1 medications.
Eli Lilly's manufacturing capacity is now sufficient to meet both current and projected demands for Mounjaro and Zepbound.
The end of the shortage restricts the sale of compounded versions of these drugs, impacting businesses like Hims & Hers and other telehealth platforms.
Patients and prescribers may still face localized supply disruptions as the drug moves through the distribution chain.
The FDA continues to caution against the use of compounded drugs, emphasizing that they are not FDA-approved and may not be as safe as brand-name medications.